(6aR)-4-(hydroxymethyl)-2,2-dimethyl-6aH-furo[3,4-d][1,3]dioxol-6-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (6aR)-4-(hydroxymethyl)-2,2-dimethyl-6aH-furo[3,4-d][1,3]dioxol-6-one
• 化学式: C₈H₁₀O₅
• 分子量: 186.16
• InChiKey: CMBVJSMAOXBHAT-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• HEPATITIS B ANTIVIRAL AGENTS
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20170253609A1

  公开（公告）日：2017-09-07

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了以下式(I)的化合物，或其药学上可接受的盐、酯或前药： X-A-Y-L-R  (I) 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰HBV生命周期的功能，并且还可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• Hamamelitannin analogues and uses thereof
  申请人：Universiteit Gent

  公开号：US10023602B2

  公开（公告）日：2018-07-17

  The present invention relates to hamamelitannin analogues, pharmaceutical compositions comprising the same, and combinations thereof with anti-microbial agents such as antibiotics or disinfectants. It in particular relates to the use of the compounds, compositions and combinations according to this invention in human or veterinary medicine, more in particular for use in the prevention and/or treatment of bacterial infections, such as Staphylococcus aureus infections, in humans or animals.

  本发明涉及金缕梅单宁类似物、包含金缕梅单宁类似物的药物组合物及其与抗微生物剂（如抗生素或消毒剂）的组合物。 本发明特别涉及根据本发明的化合物、组合物和组合物在人类或兽医中的用途，尤其是用于预防和/或治疗人类或动物的细菌感染，如金黄色葡萄球菌感染。
• Hepatitis B antiviral agents
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US10179792B2

  公开（公告）日：2019-01-15

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物或其药学上可接受的盐、酯或原药： X-A-Y-L-R (I) 其可抑制乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒 HBV 生命周期的功能，也可用作抗病毒药物。本发明进一步涉及包含上述化合物的药物组合物，用于给受 HBV 感染的患者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者 HBV 感染的方法。
• HAMAMELITANNIN ANALOGUES AND USES THEREOF
  申请人：Universiteit Gent

  公开号：US20170158727A1

  公开（公告）日：2017-06-08

  The present invention relates to hamamelitannin analogues, pharmaceutical compositions comprising the same, and combinations thereof with anti-microbial agents such as antibiotics or disinfectants. It in particular relates to the use of the compounds, compositions and combinations according to this invention in human or veterinary medicine, more in particular for use in the prevention and/or treatment of bacterial infections, such as Staphylococcus aureus infections, in humans or animals.
• [EN] HEPATITIS B ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX CONTRE L'HÉPATITE B
  申请人：ENANTA PHARM INC

  公开号：WO2017155844A1

  公开（公告）日：2017-09-14

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A -Y -L-R (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.